Tags

Type your tag names separated by a space and hit enter

Current pharmacotherapeutic treatment options in Parkinson's disease.
Dis Mon. 2007 Apr; 53(4):214-22.DM

Abstract

Treatment options for Parkinson's disease have greatly expanded in recent years. Pharmacological treatments, such as levodopa, dopamine receptor agonists, anticholinergic medications, monoamine oxidase B inhibitors, and the catechol-O-methyl transferase inhibitors, remain the mainstay of therapeutic intervention and are reviewed. Additionally, the traditional and new roles for amantadine are explained. Despite the great efficacy of levodopa, "levodopa-sparing strategies" in early Parkinson's disease are emphasized in order to delay the development of difficult-to-manage motor fluctuations and dyskinesias.

Authors+Show Affiliations

Northwestern University, Feinberg School of Medicine, Movement Disorders Program, Evanston Northwestern Healthcare, Evanston and Glenbrook Hospitals, Evanston and Glenview, Illinois, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17586328

Citation

Rezak, Michael. "Current Pharmacotherapeutic Treatment Options in Parkinson's Disease." Disease-a-month : DM, vol. 53, no. 4, 2007, pp. 214-22.
Rezak M. Current pharmacotherapeutic treatment options in Parkinson's disease. Dis Mon. 2007;53(4):214-22.
Rezak, M. (2007). Current pharmacotherapeutic treatment options in Parkinson's disease. Disease-a-month : DM, 53(4), 214-22.
Rezak M. Current Pharmacotherapeutic Treatment Options in Parkinson's Disease. Dis Mon. 2007;53(4):214-22. PubMed PMID: 17586328.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current pharmacotherapeutic treatment options in Parkinson's disease. A1 - Rezak,Michael, PY - 2007/6/26/pubmed PY - 2007/8/19/medline PY - 2007/6/26/entrez SP - 214 EP - 22 JF - Disease-a-month : DM JO - Dis Mon VL - 53 IS - 4 N2 - Treatment options for Parkinson's disease have greatly expanded in recent years. Pharmacological treatments, such as levodopa, dopamine receptor agonists, anticholinergic medications, monoamine oxidase B inhibitors, and the catechol-O-methyl transferase inhibitors, remain the mainstay of therapeutic intervention and are reviewed. Additionally, the traditional and new roles for amantadine are explained. Despite the great efficacy of levodopa, "levodopa-sparing strategies" in early Parkinson's disease are emphasized in order to delay the development of difficult-to-manage motor fluctuations and dyskinesias. SN - 0011-5029 UR - https://www.unboundmedicine.com/medline/citation/17586328/Current_pharmacotherapeutic_treatment_options_in_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0011-5029(07)00040-5 DB - PRIME DP - Unbound Medicine ER -